Evolving Paradigms in the Management of Systemic Lupus Erythematosus: An Exhaustive Review with Special Emphasis on Pharmaceuticals in Clinical Trials

Abstract: Systemic Lupus Erythematosus (SLE) is a complicated autoimmune condition characterized by a multifactorial aetiology that encompasses genetic, environmental, hormonal, and immunological variables. Notwithstanding breakthroughs in diagnostics and therapies, controlling disease progression and attaining remission continue to pose considerable clinical hurdles. This review seeks to deliver an exhaustive examination of the developing etiopathogenetic processes and treatment strategies for SLE, particularly emphasizing pharmacological medicines now under clinical evaluation. A comprehensive literature analysis was performed in esteemed databases such as PubMed, Google Scholar, Web of Science, and Scopus and significant discoveries were considered from recent epidemiological research, mechanistic insights into immunological dysregulation, and contemporary pharmaceutical methods, especially those in active or concluded clinical trials. Principal immunopathogenic factors in SLE encompass type I interferons, dysregulated T and B cell activation, dendritic cell impairment, and the generation of neutrophil extracellular traps. Understanding the intricate aetiology of SLE has facilitated the development of customized therapies that offer opportunities for improved disease management. A diverse range of biologics aimed at B cells (Rituximab, Belimumab), cytokines (Anifrolumab, Tocilizumab), and intracellular signalling pathways (JAK/STAT inhibitors) is undergoing clinical development. By critically evaluating efficacy, safety, and translational relevance, this review integrates fundamental pathological mechanisms with patient-oriented therapy approaches. Together with summarizing new treatments and trial findings, it also draws attention to the shortcomings of current treatment approaches and offers researchers and clinicians a structured framework to guide treatment choices, improve trial procedures in the future, and speed up the creation of next-generation treatments designed to improve SLE outcomes.